Literature DB >> 13948668

Basis of actinomycin action. II. Effect of actinomycin on the nucleoside triphosphate-inorganic pyrophosphate exchange.

I H GOLDBERG, M RABINOWITZ, E REICH.   

Abstract

Entities:  

Keywords:  ACTINOMYCIN; NUCLEOSIDES; NUCLEOTIDES

Mesh：

Substances：

Year:  1963        PMID： 13948668      PMCID： PMC299785          DOI： 10.1073/pnas.49.2.226

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  5 in total

1.  Enzymatic synthesis of deoxyribonucleic acid. XI. Further studies on nearest neighbor base sequences in deoxyribonucleic acids.

Authors:  M N SWARTZ; T A TRAUTNER; A KORNBERG
Journal:  J Biol Chem       Date:  1962-06       Impact factor: 5.157

2.  Basis of actinomycin action. I. DNA binding and inhibition of RNA-polymerase synthetic reactions by actinomycin.

Authors:  I H GOLDBERG; M RABINOWITZ; E REICH
Journal:  Proc Natl Acad Sci U S A       Date:  1962-12-15       Impact factor: 11.205

3.  Deoxyribo ucleic acid-directed synthesis of ribonucleic acid by an enzyme from Escherichia coli.

Authors:  M CHAMBERLIN; P BERG
Journal:  Proc Natl Acad Sci U S A       Date:  1962-01-15       Impact factor: 11.205

4.  The role of deoxyribonucleic acid in ribonucleic acid synthesis. III. The inhibition of the enzymatic synthesis of ribonucleic acid and deoxyribonucleic acid by actinomycin D and proflavin.

Authors:  J HURWITZ; J J FURTH; M MALAMY; M ALEXANDER
Journal:  Proc Natl Acad Sci U S A       Date:  1962-07-15       Impact factor: 11.205

5.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157
  5 in total
  7 in total

1.  An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.

Authors:  Ingeborg M M van Leeuwen; Bhavya Rao; Marijke C C Sachweh; Sonia Laín
Journal:  Cell Cycle       Date:  2012-05-01       Impact factor: 4.534

2.  Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Authors:  Bhavya Rao; Ingeborg M M van Leeuwen; Maureen Higgins; Johanna Campbel; Alastair M Thompson; David P Lane; Sonia Lain
Journal:  Oncotarget       Date:  2010-11

3.  Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.

Authors:  Christopher R Hill; Michael Cole; Julie Errington; Ghada Malik; Alan V Boddy; Gareth J Veal
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

4.  Actinomycin analogues containing pipecolic acid: relationship of structure to biological activity.

Authors:  J V Formica; A J Shatkin; E Katz
Journal:  J Bacteriol       Date:  1968-06       Impact factor: 3.490

5.  The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients.

Authors:  Hannah Yejin Kim; Gareth J Veal; Fanfan Zhou; Alan V Boddy
Journal:  Eur J Clin Pharmacol       Date:  2018-08-30       Impact factor: 2.953

6.  Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress.

Authors:  Juliette Humeau; Allan Sauvat; Giulia Cerrato; Wei Xie; Friedemann Loos; Francesca Iannantuoni; Lucillia Bezu; Sarah Lévesque; Juliette Paillet; Jonathan Pol; Marion Leduc; Laurence Zitvogel; Hugues de Thé; Oliver Kepp; Guido Kroemer
Journal:  EMBO Mol Med       Date:  2020-04-23       Impact factor: 12.137

7.  Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.

Authors:  Christopher R Hill; David Jamieson; Huw D Thomas; Colin D A Brown; Alan V Boddy; Gareth J Veal
Journal:  Biochem Pharmacol       Date:  2012-10-11       Impact factor: 5.858
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.